SFRP5 and metabolic dysfunction-associated steatotic liver disease: This study suggested that the increased expression of SFRP5 in VAT seems to be induced by obesity, and by NAFLD pathogenesis in SAT and VAT, with a potential protective role against metabolic imbalance.